![]() |
Name |
botryospyrone D
|
Molecular Formula | C13H16O5 | |
IUPAC Name* |
4-hydroxy-6,8-dimethoxy-3,7-dimethyl-3,4-dihydroisochromen-1-one
|
|
SMILES |
COc1cc2c(c(OC)c1C)C(=O)OC(C)C2O
|
|
InChI |
InChI=1S/C13H16O5/c1-6-9(16-3)5-8-10(12(6)17-4)13(15)18-7(2)11(8)14/h5,7,11,14H,1-4H3/t7-,11-/m0/s1
|
|
InChIKey |
VNZFGBOMNXGPEV-CPCISQLKSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 252.27 | ALogp: | 1.6 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 18 | QED Weighted: | 0.817 |
Caco-2 Permeability: | -4.726 | MDCK Permeability: | 0.00002170 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.013 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.007 |
Blood-Brain-Barrier Penetration (BBB): | 0.965 | Plasma Protein Binding (PPB): | 63.14% |
Volume Distribution (VD): | 0.746 | Fu: | 20.23% |
CYP1A2-inhibitor: | 0.354 | CYP1A2-substrate: | 0.954 |
CYP2C19-inhibitor: | 0.07 | CYP2C19-substrate: | 0.903 |
CYP2C9-inhibitor: | 0.019 | CYP2C9-substrate: | 0.818 |
CYP2D6-inhibitor: | 0.031 | CYP2D6-substrate: | 0.723 |
CYP3A4-inhibitor: | 0.056 | CYP3A4-substrate: | 0.524 |
Clearance (CL): | 7.077 | Half-life (T1/2): | 0.5 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.193 |
Drug-inuced Liver Injury (DILI): | 0.323 | AMES Toxicity: | 0.067 |
Rat Oral Acute Toxicity: | 0.098 | Maximum Recommended Daily Dose: | 0.024 |
Skin Sensitization: | 0.055 | Carcinogencity: | 0.028 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.065 |
Respiratory Toxicity: | 0.065 |